This section is intended for UK and Ireland Healthcare Professionals only. If you are a member of the public click here. If you have been prescribed Galafold click here for the patient site.

Galafold

HCP – Homepage

The first approved chaperone therapy for Fabry disease
…and it’s oral1

View the latest data

View resources to
support your patients

References
  1. Hughes DA, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet 2017;54:288–296.

PP-GA-UK-0004-0123 Date of preparation: January 2024